IDNA:NYE-iShares Genomics Immunology and Healthcare ETF (USD)

ETF | Health |

Last Closing

USD 22.8

Change

0.00 (0.00)%

Market Cap

USD 0.12B

Volume

0.02M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-02 )

ETFs Containing IDNA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 0.75% 14% F 37% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.75% 14% F 36% F
Trailing 12 Months  
Capital Gain 2.06% 19% F 41% F
Dividend Return 0.50% 44% F 5% F
Total Return 2.56% 19% F 29% F
Trailing 5 Years  
Capital Gain -21.21% 10% F 26% F
Dividend Return 3.16% 53% F 8% B-
Total Return -18.04% 14% F 17% F
Average Annual (5 Year Horizon)  
Capital Gain -5.86% 5% F 10% F
Dividend Return -5.32% 5% F 8% B-
Total Return 0.54% 53% F 14% F
Risk Return Profile  
Volatility (Standard Deviation) 31.23% 14% F 34% F
Risk Adjusted Return -17.02% 5% F 12% F
Market Capitalization 0.12B 60% D- 30% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.